Inozyme Pharma

IN THE PRESS
Inozyme Pharma was acquired by BioMarin Pharmaceuticals in July 2025.
Inozyme Pharma, Inc today announced that the Company will present recently announced topline data during oral presentations at two upcoming medical conferences.
Inozyme Pharma, Inc today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 from 6:40-7:10pm ET / 3:40-4:10pm PT.
Inozyme Pharma, Inc. today announced that it granted stock options to one new employee to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, as an inducement material to the new employees.
Inozyme Pharma, Inc. announced positive topline safety, pharmacokinetic, pharmacodynamic and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency.
Inozyme Pharma, Inc. announced that it granted stock options to three new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, as inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635.
Inozyme Pharma, Inc today announced that Doug Treco, Ph.D., the company’s chief executive officer and chairman of the board, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024.
Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host a conference call and webcast on Monday, April 8, 2024 at 8:00 a.m. Eastern Time.
Inozyme Pharma, Inc. today reported financial results for the full year ended December 31, 2023, and provided recent business highlights.
Inozyme Pharma, Inc. today announced Douglas A. Treco, Ph.D., the Company’s chief executive officer and chairman of the board, will participate in an Orphan Bone & Neuromuscular Diseases panel presentation at the TD Cowen 44th Annual Health Care Conference.
Inozyme Pharma, Inc. today announced that it granted stock options to four new employees to purchase shares of the Company’s common stock.
NEWS
Why I advocated on Capitol Hill this month for the renewal of the FDA’s Priority Review Voucher program
Money on the Move: A weekly roundup of notable funding news across biopharma industry. See who raked in funds for which diseases
Prometheus completed its Phase II trial in UC, Algernon announced its Phase II trial of IPF and chronic coffee, Seelos dosed the first patient of SLS-005 for patients with ALS.
Third Harmonic Bio, Akili Interactive, the Rare Disease Company Coalition, Inozyme, Athira, Cytovia and many more made major leadership decisions this week.
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers
The grant is the latest in a steady stream of company advances highlighted by the addition of a chief financial officer in January and several collaborative agreements in the past year.
With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look.